Category
117 releases
Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned…
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2026 of $1.73 per share on outstanding…
Research conducted in partnership with University College London examines personalised dosing, clinical monitoring and metabolic health outcomes in…
The JAK inhibitors market is expected to witness steady growth, driven by the increasing prevalence of autoimmune and inflammatory diseases, growing…
Northwest Biotherapeutics (OTCQB: NWBO) NWBio a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,…
Made Scientific to integrate multiple UniFuge® single-use centrifugation systems across its Princeton, NJ, and East Norriton, PA, facilities to…
Median overall survival of 12 months with RBS2418 monotherapy in subjects with heavily pretreated tumors that express ENPP1 and cGAS proteins…
A new drug is effective at decreasing recurrence of and death from endometrial cancer, a landmark international study shows. The drug, called…
Sword Bio and Alturas Analytics today announced a strategic collaboration designed to provide biotechnology and pharmaceutical companies with…
A study coauthored by Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD is among the…
Celebrating the clinically proven treatment that has become the leader*1 in professional microneedling NASHVILLE, Tenn., Oct. 26, 2026 — Revance, a…
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human…
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
Automated system enables rapid, reproducible formulation screening with minimal sample consumption Completes the NanoCalibur® Series (Mini, Lab, Pro,…
Powered by whole-genome sequencing and MAESTRO* technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to…
No dose-limiting toxicities and no Grade ≥2 treatment-emergent adverse events through four dose levels; Plasma exposures exceed those predicted by…
Vantive plans to expand its HomeAdvantage offering with the next-generation Avira automated peritoneal dialysis cycler, which is progressing through…
Company to Attend BIO-Europe in Cologne, Germany, and Present a Scientific Poster at Drug Discovery Chemistry Europe in Barcelona, Spain REHOVOT,…
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading…
BreakBio, a biotech company developing personalized drugs for cancer, today announced that Stephen M. Hahn, M.D., former Commissioner of the U.S.…
